You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》建銀國際升康方生物(09926.HK)目標價至59元 前景更光明
阿思達克 03-20 15:48
建銀國際表示,康方生物(09926.HK)去年淨虧損20億人民幣,較預期少9%;去年下半年淨虧損較預期少26%。撇除非經常性項目,特別是去年上半年的一次性預付現金獎勵,全年淨虧損為8.14億元人民幣,明顯優於2022年的淨虧損11億元人民幣。該行將業績改善歸因於產品毛利率改善,以及營運支出佔銷售比率較低。 去年AK104續大放異彩,銷售達14億人民幣,高於市場預期,該行亦上調AK104今明兩年銷售預測27%及25%,分別至18億元人民幣及25億元人民幣,整體收入預測亦上調14%及11%,至29億元人民幣及44億元人民幣。今年淨虧損預測減少3%至4.39億元。2025年淨利潤預測維持6.06億元人民幣。目標價由58元升至59元,評級維持「跑贏大市」。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account